Department of Hematology and Medical Oncology, Emory University, Atlanta, GA.
Department of Medicine, University of Rochester, Rochester, NY.
Clin Breast Cancer. 2021 Dec;21(6):509-520. doi: 10.1016/j.clbc.2021.09.003. Epub 2021 Sep 17.
Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatments for TNBC. To update recent developments, this article comprehensively reviews molecular classification and biomarkers of TNBC and targeted therapy developments in immunotherapy, PARP and AKT pathway inhibitors, antibody-drug conjugates and androgen receptor blockade. The treatment of TNBC has dramatically evolved beyond basic cytotoxic chemotherapy into an expanding domain of targeted therapies tailored to the heterogeneity of this complex and aggressive disease. Progress will continue through the sustained and devoted efforts of our investigators and the patients who dedicatedly enroll in clinical trials. Through a daring persistence to challenge the status quo we now have the opportunity to offer our patients with TNBC a new sense of hope.
三阴性乳腺癌（TNBC）占所有原发性乳腺癌的 15%至 20%，是乳腺癌中最具侵袭性的亚型。针对 TNBC 的靶向治疗和生物标志物的开发已经取得了快速进展，以确定最佳治疗方法。为了更新最新进展，本文全面综述了 TNBC 的分子分类和生物标志物，以及免疫治疗、PARP 和 AKT 通路抑制剂、抗体药物偶联物和雄激素受体阻断剂的靶向治疗进展。TNBC 的治疗已经从基础细胞毒性化疗显著发展为针对这种复杂和侵袭性疾病异质性的靶向治疗领域。通过我们的研究人员和专门参加临床试验的患者的持续努力，进展将继续。通过勇敢地坚持挑战现状，我们现在有机会为患有 TNBC 的患者带来新的希望。
